Eventus attracts $2.72M for breast cancer Dx testing and commercial expansion

Eventus Diagnostics in Miami raised a $2.72 million investment infusion that it will use to advance its Octava breast cancer diagnostic blood tests. They are designed for use along with annual mammograms to spot cancer or determine its absence by measuring ratios of autoantibodies produced in response to tumor-specific antigens. Octava tests have a CE mark and also recently won Israeli regulatory approval. More clinical studies are underway to provide additional data for a U.S. FDA submission. The funding comes from a new family office private investor, plus existing investors. Release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.